We are live on
!
Find out more
Antipodes Partners Portfolio holdings
AUM
$5.46B
Turnover
36.94%
1-Year Est. Return
26.64%
This Fund
S&P 500
This Quarter
Est. Return
+5.97%
1 Year Est. Return
+26.64%
3 Year Est. Return
+96.4%
5 Year Est. Return
+160.76%
10 Year Est. Return
–
AUM
$4.76B
AUM Growth
+$305M
(+6.8%)
Cap. Flow
+$54.5M
Cap. Flow
% of AUM
1.14%
Top 10 Holdings %
Top 10 Hldgs %
37.47%
Holding
149
New
33
Increased
46
Reduced
42
Closed
19
Avg Time Held Equity + Options
0.9
years
Top 10 Avg Time Held Equity + Options
1.7
years
Top 20 Avg Time Held Equity + Options
1.7
years
Avg Time Held Equity only
1
year
Top 10 Avg Time Held Equity only
1.7
years
Top 20 Avg Time Held Equity only
1.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$120M |
| 2 |
TotalEnergies
TTE
|
+$87.9M |
| 3 |
Amazon
AMZN
|
+$68.8M |
| 4 |
Microsoft
MSFT
|
+$58.4M |
| 5 |
Oracle
ORCL
|
+$57.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$153M |
| 2 |
Advanced Micro Devices
AMD
|
+$90.6M |
| 3 |
Johnson Controls International
JCI
|
+$82.5M |
| 4 |
Alcon
ALC
|
+$48.2M |
| 5 |
Barrick Mining
B
|
+$43.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Utilities | 25.97% |
| 2 | Technology | 13.9% |
| 3 | Healthcare | 12.33% |
| 4 | Financials | 8.66% |
| 5 | Consumer Discretionary | 8.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Waters Corp
WAT
$43.6B
| $66.5K | ﹤0.01% |
175
+87
| +99% | +$32K |
2025 Q3
1 quarter
|
|
102
Teva Pharmaceutical Industries Limited
TEVA
$47.9B
| $65.1K | ﹤0.01% |
+2,086
| New | +$51.4K |
2025 Q4
0 quarters
|
|
103
Vertex Pharmaceuticals
VRTX
$129B
| $57.6K | ﹤0.01% |
+127
| New | +$54.7K |
2025 Q4
0 quarters
|
|
104
DexCom
DXCM
$33.1B
| $57K | ﹤0.01% |
858
-759
| -47% | -$49.1K |
2025 Q1
3 quarters
|
|
105
DELISTED
Amicus Therapeutics
FOLD
| $55.9K | ﹤0.01% |
3,926
| – | – |
2025 Q3
1 quarter
|
|
106
DELISTED
Apogee Therapeutics
APGE
| $54.6K | ﹤0.01% |
723
-120
| -14% | -$7.56K |
2025 Q1
3 quarters
|
|
107
Novanta
NOVT
$5.1B
| $53.4K | ﹤0.01% |
+449
| New | +$51.1K |
2025 Q4
0 quarters
|
|
108
GE Aerospace
GE
$324B
| $43.4K | ﹤0.01% |
141
+4
| +3% | +$1.2K |
2023 Q4
8 quarters
|
|
109
Tango Therapeutics
TNGX
$3.83B
| $40K | ﹤0.01% |
+4,513
| New | +$38.9K |
2025 Q4
0 quarters
|
|
110
Ingersoll Rand
IR
$30.2B
| $39.8K | ﹤0.01% |
502
+16
| +3% | +$1.26K |
2023 Q4
8 quarters
|
|
111
IDEAYA Biosciences
IDYA
$3.27B
| $39.8K | ﹤0.01% |
1,150
+380
| +49% | +$12.1K |
2025 Q3
1 quarter
|
|
112
DELISTED
Nuvalent
NUVL
| $39.3K | ﹤0.01% |
391
| – | – |
2025 Q1
3 quarters
|
|
113
Cabaletta Bio
CABA
$263M
| $37.6K | ﹤0.01% |
+17,187
| New | +$42.6K |
2025 Q4
0 quarters
|
|
114
Viridian Therapeutics
VRDN
$2.22B
| $35.8K | ﹤0.01% |
+1,150
| New | +$31.5K |
2025 Q4
0 quarters
|
|
115
iRhythm Holdings
IRTC
$3.6B
| $33.5K | ﹤0.01% |
189
-31
| -14% | -$5.49K |
2025 Q2
2 quarters
|
|
116
Disc Medicine
IRON
$2.17B
| $33.3K | ﹤0.01% |
+419
| New | +$35.4K |
2025 Q4
0 quarters
|
|
117
PUT
Structure Therapeutics
GPCR
$1.58B
| $30K | ﹤0.01% |
+48
| New | +$1.96K |
2025 Q4
0 quarters
|
|
118
SI-BONE Inc
SIBN
$892M
| $29K | ﹤0.01% |
+1,470
| New | +$25.5K |
2025 Q4
0 quarters
|
|
119
DELISTED
AtaiBeckley Inc
ATAI
| $29K | ﹤0.01% |
+7,081
| New | +$33.4K |
2025 Q4
0 quarters
|
|
120
908 Devices
MASS
$491M
| $26.7K | ﹤0.01% |
5,094
-133
| -3% | -$929 |
2025 Q1
3 quarters
|
|
121
DELISTED
Day One Biopharmaceuticals
DAWN
| $23.9K | ﹤0.01% |
2,559
+828
| +48% | +$6.92K |
2025 Q1
3 quarters
|
|
122
Oric Pharmaceuticals
ORIC
$1.32B
| $19.6K | ﹤0.01% |
2,399
-502
| -17% | -$5.78K |
2025 Q1
3 quarters
|
|
123
Certara
CERT
$1.47B
| $19.3K | ﹤0.01% |
2,190
-10,095
| -82% | -$104K |
2024 Q3
5 quarters
|
|
124
Dianthus Therapeutics
DNTH
$4.17B
| $18.9K | ﹤0.01% |
+459
| New | +$17.8K |
2025 Q4
0 quarters
|
|
125
Sagimet Biosciences
SGMT
$579M
| $18.8K | ﹤0.01% |
3,176
| – | – |
2025 Q2
2 quarters
|
|
Similar funds
SCM
Antipodes Partners's Q4 2025 Portfolio in Review
As of Q4 2025, Antipodes Partners held 149 positions worth $4.76B, up 6.8% from $4.46B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Antipodes Partners's Q4 2025 filing shows 33 new, 46 increased, 42 reduced and 19 closed positions. Its largest new stake was Meta Platforms (Facebook): 179,243 shares worth $118M. The largest sale was Alphabet (Google) Class A, an estimated $153M.
By sector, the portfolio is most concentrated in Utilities at 26% of assets, down from 29% a quarter earlier, followed by Technology and Healthcare.
- Antipodes Partners's largest Q4 2025 buy was Meta Platforms (Facebook): 179,243 shares worth $118M.
- Antipodes Partners added most to Amazon in Q4 2025, an estimated $68.8M increase.
- Antipodes Partners's biggest Q4 2025 reduction was Advanced Micro Devices, cutting an estimated $90.6M.
- Antipodes Partners fully exited Alphabet (Google) Class A in Q4 2025, selling an estimated $153M.
- Antipodes Partners's ten largest holdings make up 37% of its $4.76B portfolio in Q4 2025.
- Antipodes Partners opened 33 new positions and closed 19 in Q4 2025.
- Antipodes Partners's portfolio value rose 6.8% quarter-over-quarter to $4.76B.
Based on Antipodes Partners's 13F filing for Q4 2025, filed 5 Feb 2026.